FDA expands cystic fibrosis treatment approval to children ages 6 to 12
(HealthDay)—The indication for a cystic fibrosis treatment, Symdeko (tezacaftor/ivacaftor) tablets, has been expanded to treat children ages 6 years and older with cystic fibrosis and certain genetic mutations, the U.S. ...
Jun 24, 2019
0
0